Fierce Pharma

SEPTEMBER 22, 2023

Merck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break. Merck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break.

Clinical Trials 129

Clinical Trials Clinical Trials Trials 129

Drug Discovery World

OCTOBER 31, 2022

The last month has seen huge strides forward in our understanding of cancers, particularly in how they develop resistance to therapies and how we can ‘outsmart’ them using gene editing or different therapeutic pathways, but also how we can better target drugs to individuals and accurately predict treatment outcomes.

Drugs 52

Drugs Research Gene Editing Protein 52

World of DTC Marketing

DECEMBER 13, 2021

OPENING: American cancer patients spent more than $21 billion on their care in 2019. As cancer survival rates rise, so do the price tags of life-saving treatments. Some cancer patients may face out-of-pocket costs of nearly $12,000 a year for one drug. What makes cancer such a financial killer? ScienceNews.com.

Drugs 55

Drugs FDA Approval Medicine Containment 55

XTalks

AUGUST 17, 2020

To learn more about innovations in the field, Xtalks spoke to Anish Suri, PhD, president and chief scientific officer of Cue Biopharma about the company’s initiatives in the development of immune-based biological compounds for the treatment of cancers and autoimmune diseases. Cell-Based Immunotherapy vs. Immune Biologics. asks Dr. Suri.

Protein 98

Protein Engineer Immune Response In-Vivo 98

Drug Discovery World

APRIL 17, 2023

Totus Medicines has dosed its first patient in a Phase I clinical trial of TOS-358, a first-in-class covalent PI3Kα inhibitor for the treatment of numerous cancers with known PIK3CA mutations. The study will be conducted in two parts.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Medicine 52